Diabetes, Vol 45, Issue 10 1289-1298, Copyright © 1996 by American Diabetes Association

ARTICLES

The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial

The Diabetes Control and Complications Trial (DCCT) demonstrated a reduction in the development and progression of the long-term complications of IDDM with intensive therapy aimed at achieving glycemic control as close to the nondiabetic range as possible. The DCCT subsequently showed that the total lifetime exposure to glycemia was the principal determinant of the risk of retinopathy and that there was a continuous nonlinear relationship between this risk and the mean level of HbA1c (DCCT Research Group, Diabetes 44:968-993, 1995). In contrast, other authors, based on a retrospective study (Krolewski et al., N Engl J Med 332:1251-1255, 1995), have suggested that a glycemic threshold for microabuminuria and for retinopathy exists at an HbA1c level of approximately 8%, below which there is no further appreciable reduction in risk. In this perspective, we examine whether the DCCT data demonstrate such a glycemic threshold for the development of retinopathy, nephropathy, or neuropathy. In the DCCT, 1,441 patients with IDDM were randomly assigned to intensive (n = 711) or conventional (n = 730) therapy and followed for a mean of 6.5 years. Retinopathy was assessed every 6 months by stereoscopic fundus photography; albumin excretion was measured annually in a 4-h collection; and neuropathy was assessed with a standardized protocol performed at baseline and at 5 years. Glycosylated hemoglobin was measured quarterly. Episodes of severe hypoglycemia were ascertained using standardized procedures. The risks (hazard rates) of retinopathy progression and of developing microalbuminuria and neuropathy were found to be continuous but nonlinear over the entire range of glycosylated hemoglobin values in the intensive, conventional, and combined treatment groups. These nonlinear relationships describe a constant relative risk gradient in which proportional reductions in HbA1c are accompanied by proportional reductions in the risk of complications. Although the magnitude of the absolute risk reduction declines with continuing proportional reductions in HbA1c, there are still meaningful further reductions in risk as the HbA1c is reduced toward the normal range. When the instantaneous risks for different complications associated with different HbA1c values are compounded over time, there are substantial differences in the cumulative incidence of patients experiencing a complication for patients with HbA1c values of 6 vs. 7 vs. 8% or higher. In fact, no HbA1c threshold could be identified, short of normal glycemia, below which there was no risk of the development or progression of these complications. Furthermore, as the HbA1c was reduced proportionately, the proportional rate of decline in the relative risk for each of these complications was similar for HbA1c levels < or = 8.0% and for levels > 8%. In contrast, although the absolute risk of severe hypoglycemia in the intensive treatment group increased as the HbA1c decreased, the relative risk gradients were significantly less for HbA1c levels < or = 8.0% than for levels > 8%. These extensive prospective DCCT data do not support the conjecture that a glycemic threshold for the development of complications exists at an HbA1c of 8% or that an HbA1c goal of 8% is maximally beneficial. In the DCCT, as HbA1c was reduced below 8% there were continuing relative reductions in the risk of complications, whereas there was a slower rate of increase in the risk of hypoglycemia. Therefore, the DCCT continues to recommend implementation of intensive therapy with the goal of achieving normal glycemia as early as possible in as many IDDM patients as is safely possible.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. M. Lachin, S. Genuth, D. M. Nathan, B. Zinman, B. N. Rutledge, and for the DCCT/EDIC Research Group Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial--Revisited Diabetes, April 1, 2008; 57(4): 995 - 1001. [Abstract] [Full Text] [PDF]

				T. R. Nansel, R. J. Iannotti, B. G. Simons-Morton, C. Cox, L. P. Plotnick, L. M. Clark, and L. Zeitzoff Diabetes Personal Trainer Outcomes: Short-term and 1-year outcomes of a diabetes personal trainer intervention among youth with type 1 diabetes Diabetes Care, October 1, 2007; 30(10): 2471 - 2477. [Abstract] [Full Text] [PDF]

				K. Raile, A. Galler, S. Hofer, A. Herbst, D. Dunstheimer, P. Busch, and R. W. Holl Diabetic Nephropathy in 27,805 Children, Adolescents, and Adults With Type 1 Diabetes: Effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex Diabetes Care, October 1, 2007; 30(10): 2523 - 2528. [Abstract] [Full Text] [PDF]

				J. M. Lachin, S. Genuth, D. M. Nathan, and B. N. Rutledge The Hemoglobin Glycation Index Is Not an Independent Predictor of the Risk of Microvascular Complications in the Diabetes Control and Complications Trial Diabetes, July 1, 2007; 56(7): 1913 - 1921. [Abstract] [Full Text] [PDF]

				The Mount Hood 4 Modeling Group Computer Modeling of Diabetes and Its Complications: A report on the Fourth Mount Hood Challenge Meeting Diabetes Care, June 1, 2007; 30(6): 1638 - 1646. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74. [Full Text] [PDF]

				J. Dilley, A. Ganesan, R. Deepa, M. Deepa, G. Sharada, O. D. Williams, and V. Mohan Association of A1C With Cardiovascular Disease and Metabolic Syndrome in Asian Indians With Normal Glucose Tolerance Diabetes Care, June 1, 2007; 30(6): 1527 - 1532. [Abstract] [Full Text] [PDF]

				L. Pogach, M. Engelgau, and D. Aron Measuring Progress Toward Achieving Hemoglobin A1c Goals in Diabetes Care: Pass/Fail or Partial Credit JAMA, February 7, 2007; 297(5): 520 - 523. [Full Text] [PDF]

				Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J., January 1, 2007; 28(1): 88 - 136. [Full Text] [PDF]

				J. M. Boltri, M. Davis-Smith, L. E. Zayas, S. Shellenberger, J. P. Seale, T. W. Blalock, and A. Mbadinuju Developing a Church-Based Diabetes Prevention Program With African Americans: Focus Group Findings The Diabetes Educator, November 1, 2006; 32(6): 901 - 909. [Abstract] [Full Text] [PDF]

				R. J. Iannotti, T. R. Nansel, S. Schneider, D. L. Haynie, B. Simons-Morton, D. O. Sobel, L. Zeitzoff, L. P. Plotnick, and L. Clark Assessing Regimen Adherence of Adolescents With Type 1 Diabetes Diabetes Care, October 1, 2006; 29(10): 2263 - 2267. [Abstract] [Full Text] [PDF]

				E. S. Kilpatrick, A. S. Rigby, and S. L. Atkin The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes Diabetes Care, July 1, 2006; 29(7): 1486 - 1490. [Abstract] [Full Text] [PDF]

				C. D. Saudek, R. L. Derr, and R. R. Kalyani Assessing Glycemia in Diabetes Using Self-monitoring Blood Glucose and Hemoglobin A1c JAMA, April 12, 2006; 295(14): 1688 - 1697. [Abstract] [Full Text] [PDF]

				P. Fioretto, M. Bruseghin, I. Berto, P. Gallina, E. Manzato, and M. Mussap Renal Protection in Diabetes: Role of Glycemic Control J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S86 - S89. [Abstract] [Full Text] [PDF]

				S. H. Jee, L. E. Boulware, E. Guallar, I. Suh, L. J. Appel, and E. R. Miller III Direct, Progressive Association of Cardiovascular Risk Factors With Incident Proteinuria: Results From the Korea Medical Insurance Corporation (KMIC) Study Arch Intern Med, October 24, 2005; 165(19): 2299 - 2304. [Abstract] [Full Text] [PDF]

				C. L. Martin Case Study: Whose Diabetes Is It Anyway? Diabetes Self-Management After a Stroke Diabetes Spectr, October 1, 2005; 18(4): 196 - 198. [Full Text] [PDF]

				J. Rich and J. C. Lee The Pathogenesis of Staphylococcus aureus Infection in the Diabetic NOD Mouse Diabetes, October 1, 2005; 54(10): 2904 - 2910. [Abstract] [Full Text] [PDF]

				J. Gerich, P. Raskin, L. Jean-Louis, D. Purkayastha, and M. A. Baron PRESERVE-{beta}: Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin Diabetes Care, September 1, 2005; 28(9): 2093 - 2099. [Abstract] [Full Text] [PDF]

				P. J. Dyck, P. C. O'Brien, W. J. Litchy, C. M. Harper, C. J. Klein, and P. J. B. Dyck Monotonicity of Nerve Tests in Diabetes: Subclinical nerve dysfunction precedes diagnosis of polyneuropathy Diabetes Care, September 1, 2005; 28(9): 2192 - 2200. [Abstract] [Full Text] [PDF]

				H. U. Janka, G. Plewe, M. C. Riddle, C. Kliebe-Frisch, M. A. Schweitzer, and H. Yki-Jarvinen Comparison of Basal Insulin Added to Oral Agents Versus Twice-Daily Premixed Insulin as Initial Insulin Therapy for Type 2 Diabetes Diabetes Care, February 1, 2005; 28(2): 254 - 259. [Abstract] [Full Text] [PDF]

				Y. C. Kudva, A. Basu, G. D. Jenkins, G. M. Pons, L. L. Quandt, J. A. Gebel, D. A. Vogelsang, S. A. Smith, R. A. Rizza, and W. L. Isley Randomized Controlled Clinical Trial of Glargine Versus Ultralente Insulin in the Treatment of Type 1 Diabetes Diabetes Care, January 1, 2005; 28(1): 10 - 14. [Abstract] [Full Text] [PDF]

				S M Marshall Recent advances in diabetic nephropathy Postgrad. Med. J., November 1, 2004; 80(949): 624 - 633. [Abstract] [Full Text] [PDF]

				A. Ceriello, M. Hanefeld, L. Leiter, L. Monnier, A. Moses, D. Owens, N. Tajima, J. Tuomilehto, and for the International Prandial Glucose Regulation Postprandial Glucose Regulation and Diabetic Complications Arch Intern Med, October 25, 2004; 164(19): 2090 - 2095. [Abstract] [Full Text] [PDF]

				D. S. Fong, L. P. Aiello, F. L. Ferris III, and R. Klein Diabetic Retinopathy Diabetes Care, October 1, 2004; 27(10): 2540 - 2553. [Full Text] [PDF]

				J. Menne, J.-K. Park, M. Boehne, M. Elger, C. Lindschau, T. Kirsch, M. Meier, F. Gueler, A. Fiebeler, F. H. Bahlmann, et al. Diminished Loss of Proteoglycans and Lack of Albuminuria in Protein Kinase C-{alpha}--Deficient Diabetic Mice Diabetes, August 1, 2004; 53(8): 2101 - 2109. [Abstract] [Full Text] [PDF]

				E. L. Fanning, B. J. Selwyn, A. C. Larme, and R. A. DeFronzo Improving Efficacy of Diabetes Management Using Treatment Algorithms in a Mainly Hispanic Population Diabetes Care, July 1, 2004; 27(7): 1638 - 1646. [Abstract] [Full Text] [PDF]

				K. Hermansen, T. Ronnemaa, A. H. Petersen, S. Bellaire, and U. Adamson Intensive Therapy With Inhaled Insulin via the AERx Insulin Diabetes Management System: A 12-week proof-of-concept trial in patients with type 2 diabetes Diabetes Care, January 1, 2004; 27(1): 162 - 167. [Abstract] [Full Text] [PDF]

				Writing Team for the Diabetes Control and Complica Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic Nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study JAMA, October 22, 2003; 290(16): 2159 - 2167. [Abstract] [Full Text] [PDF]

				N. Weintrob, H. Benzaquen, A. Galatzer, S. Shalitin, L. Lazar, G. Fayman, P. Lilos, Z. Dickerman, and M. Phillip Comparison of Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Regimens in Children With Type 1 Diabetes: A Randomized Open Crossover Trial Pediatrics, September 1, 2003; 112(3): 559 - 564. [Abstract] [Full Text] [PDF]

				J. Lauenborg, E. Mathiesen, P. Ovesen, J. G. Westergaard, P. Ekbom, L. Molsted-Pedersen, and P. Damm Audit on Stillbirths in Women With Pregestational Type 1 Diabetes Diabetes Care, May 1, 2003; 26(5): 1385 - 1389. [Abstract] [Full Text] [PDF]

				Y. M. Cho, K. S. Park, H. S. Jung, H. J. Jeon, C. Ahn, J. Ha, S. J. Kim, B. D. Rhee, S. Y. Kim, and H. K. Lee High Incidence of Tacrolimus-Associated Posttransplantation Diabetes in the Korean Renal Allograft Recipients According to American Diabetes Association Criteria Diabetes Care, April 1, 2003; 26(4): 1123 - 1128. [Abstract] [Full Text] [PDF]

				P. Vague, J.-L. Selam, S. Skeie, I. De Leeuw, J. W.F. Elte, H. Haahr, A. Kristensen, and E. Draeger Insulin Detemir Is Associated With More Predictable Glycemic Control and Reduced Risk of Hypoglycemia Than NPH Insulin in Patients With Type 1 Diabetes on a Basal-Bolus Regimen With Premeal Insulin Aspart Diabetes Care, March 1, 2003; 26(3): 590 - 596. [Abstract] [Full Text] [PDF]

				A. Himmelmann, J. Jendle, A. Mellen, A. H. Petersen, U. L. Dahl, and P. Wollmer The Impact of Smoking on Inhaled Insulin Diabetes Care, March 1, 2003; 26(3): 677 - 682. [Abstract] [Full Text] [PDF]

				I. Sakurabayashi, T. Watano, S. Yonehara, K. Ishimaru, K. Hirai, T. Komori, and M. Yagi New Enzymatic Assay for Glycohemoglobin Clin. Chem., February 1, 2003; 49(2): 269 - 274. [Abstract] [Full Text] [PDF]

				Implications of the Diabetes Control and Complications Trial Diabetes Care, January 1, 2003; 26(90001): s25 - 27. [Full Text] [PDF]

				J. B. Meigs, R. B. D'Agostino Sr., D. M. Nathan, N. Rifai, and P. W.F. Wilson Longitudinal Association of Glycemia and Microalbuminuria: The Framingham Offspring Study Diabetes Care, June 1, 2002; 25(6): 977 - 983. [Abstract] [Full Text] [PDF]

				The Writing Team for the Diabetes Control and Comp Effect of Intensive Therapy on the Microvascular Complications of Type 1 Diabetes Mellitus JAMA, May 15, 2002; 287(19): 2563 - 2569. [Abstract] [Full Text] [PDF]

				R Klein and B E K Klein Blood pressure control and diabetic retinopathy Br. J. Ophthalmol., April 1, 2002; 86(4): 365 - 367. [Full Text] [PDF]

				J. Pickup, M. Mattock, and S. Kerry Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials BMJ, March 23, 2002; 324(7339): 705 - 705. [Abstract] [Full Text] [PDF]

				R. R. Little, C. L. Rohlfing, H.-M. Wiedmeyer, G. L. Myers, D. B. Sacks, and D. E. Goldstein The National Glycohemoglobin Standardization Program: A Five-Year Progress Report Clin. Chem., November 1, 2001; 47(11): 1985 - 1992. [Abstract] [Full Text] [PDF]

				R J Jarrett, E. Lamb, K.-T. Khaw, N. Wareham, and V. Vlassov Glycated haemoglobin, diabetes, and mortality in men BMJ, April 21, 2001; 322(7292): 996 - 996. [Full Text]

				W. H. Herman and M. M. Engelgau Catch-22: A response to Davidson Diabetes Care, February 1, 2001; 24(2): 415 - 415. [Full Text]

				A. K. Maniatis, G. J. Klingensmith, R. H. Slover, C. J. Mowry, and H. P. Chase Continuous Subcutaneous Insulin Infusion Therapy for Children and Adolescents: An Option for Routine Diabetes Care Pediatrics, February 1, 2001; 107(2): 351 - 356. [Abstract] [Full Text]

				K.-T. Khaw, N. Wareham, R. Luben, S. Bingham, S. Oakes, A. Welch, and N. Day Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) BMJ, January 6, 2001; 322(7277): 15 - 15. [Abstract] [Full Text] [PDF]

				I. M Stratton, A. I Adler, H A. W Neil, D. R Matthews, S. E Manley, C. A Cull, D. Hadden, R. C Turner, and R. R Holman Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ, August 12, 2000; 321(7258): 405 - 412. [Abstract] [Full Text]

				E. S Kilpatrick Glycated haemoglobin in the year 2000 J. Clin. Pathol., May 1, 2000; 53(5): 335 - 339. [Full Text] [PDF]

				The Diabetes Control and Complications Trial/Epide Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy N. Engl. J. Med., February 10, 2000; 342(6): 381 - 389. [Abstract] [Full Text] [PDF]

				S. M Virtanen, K. Ylönen, L. Räsänen, E. Ala-Venna, J. Mäenpää, and H. K Åkerblom Two year prospective dietary survey of newly diagnosed children with diabetes aged less than 6 years Arch. Dis. Child., January 1, 2000; 82(1): 21 - 26. [Abstract] [Full Text]

				R. A. DeFronzo Pharmacologic Therapy for Type 2 Diabetes Mellitus Ann Intern Med, August 17, 1999; 131(4): 281 - 303. [Abstract] [Full Text] [PDF]

				W. H Herman Clinical evidence: Glycaemic control in diabetes BMJ, July 10, 1999; 319(7202): 104 - 106. [Full Text]

				E. A. Boland, M. Grey, J. A. Mezger, and W. V. Tamborlane A Summer Vacation From Diabetes: Evidence From a Clinical Trial The Diabetes Educator, January 1, 1999; 25(1): 31 - 40. [Abstract] [PDF]

				L. Luzi Pancreas Transplantation and Diabetic Complications N. Engl. J. Med., July 9, 1998; 339(2): 115 - 117. [Full Text]

				T. Mandrup-Poulsen Recent advances: Diabetes BMJ, April 18, 1998; 316(7139): 1221 - 1225. [Full Text]

				S. Schwartz, P. Raskin, V. Fonseca, J. F. Graveline, and The Troglitazone and Exogenous Insulin Study Group Effect of Troglitazone in Insulin-Treated Patients with Type II Diabetes Mellitus N. Engl. J. Med., March 26, 1998; 338(13): 861 - 866. [Abstract] [Full Text] [PDF]

				E A Davis, B Keating, G C Byrne, M Russell, and T W Jones Impact of improved glycaemic control on rates of hypoglycaemia in insulin dependent diabetes mellitus Arch. Dis. Child., February 1, 1998; 78(2): 111 - 115. [Abstract] [Full Text]

				G. Targher, M. Alberiche, M. B. Zenere, R. C. Bonadonna, M. Muggeo, and E. Bonora Cigarette Smoking and Insulin Resistance in Patients with Noninsulin-Dependent Diabetes Mellitus J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3619 - 3624. [Abstract] [Full Text] [PDF]